SummaryWest Pharmaceutical Services delivered a strong 2Q26, beating on both revenue ($872.3M, +13.8% YoY) and EPS ($2.37, +$0.29 vs. consensus).WST raised full-year guidance to $3.345–$3.380B in sales and $8.85–$9.05 in EPS, reflecting confidence in sustained double-digit organic growth and margin expansion.High-Value Product components and biologics drove mix shift, with HVP now 49% of revenue and biologics up 29% organically, supporting durable margin gains.Valuation remains rich at 41x forward earnings, but the premium is justified by high-quality compounding, visible growth pillars, and conservative guidance. nortonrsx/iStock via Getty Images
Thesis West Pharmaceutical Services, Inc. (WST) delivered a clean beat this week. 2Q26 adjusted EPS came in at $2.37, a $0.29 beat over the consensus, with revenue managing to hit $872.3 million. That revenue figure is up 13.8% YoY and also
1.69K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
3 Dividend Champions with room for dividend growthWest Pharmaceutical Services NYSE: WST raised its full-year 2026 outlook after reporting second-quarter results that topped management’s expectations, supported by strong demand for high-value product components, biologics-related offerings and GLP-1 elastomers.
Chief Executive Officer and Board Chair Eric Green said revenue reached $872 million, up 13% organically, while adjusted earnings per share rose 29% from the prior year to $2.37. Green said the performance reflected “execution of our strategy and continued operational excellence initiatives,” as well as recovery efforts following a cyber incident during the quarter.
Get WST alerts:
What Factors Will Drive S&P 500 Performance This Year?“Given the robust outcome in the second quarter and the ongoing momentum in the business, we are raising our guidance for full year 2026,” Green said.
High-value components drive quarterly growth West’s Proprietary Products segment delivered 16% organic growth, led by the biologics market group, which rose 29% organically. The company’s high-value product, or HVP, components business generated $424 million in revenue and grew 18.4% organically, according to Chief Financial Officer Bob McMahon.
Healthcare Stocks With at Least 30 Years of Dividend IncreasesGreen said HVP components now account for 49% of total company revenue, up from 46% in the prior-year quarter. He pointed to three main growth drivers: biologics and biosimilars, HVP upgrades including Annex 1-related demand, and continued strength in GLP-1 elastomers.
Non-GLP-1 HVP components grew in the high teens on an organic basis and were the largest contributors to the company’s outperformance in the quarter, Green said. He added that West continues to see win rates above 90% for new biologic molecules, which often require higher-quality containment products such as FluroTec and NovaPure.
Management also emphasized the biosimilars opportunity. Green said biosimilar launches can expand therapy use and may allow West to maintain or increase component demand after commercialization.
Annex 1 upgrades and GLP-1 demand remain key themes Green said West is seeing more customers upgrade to HVP components, often adding finishing processes such as Envision inspection. He described the Annex 1-related opportunity as being in the early stages of a multi-year transition and said it remains on track to contribute 200 basis points of revenue growth in 2026.
During the question-and-answer portion of the call, Green said West had “just shy of 800 total projects in hand” related to Annex 1 and other HVP upgrades, up 50% from the same period last year. McMahon added that the company is seeing possible “spillover” opportunities beyond Europe, including in the United States.
GLP-1 HVP component revenue increased in the high teens, slightly ahead of company expectations. Green said West believes global adoption of GLP-1 therapies remains in the early stages and that injectables continue to show efficacy advantages compared with oral alternatives. He also said oral GLP-1 products appear to be expanding the overall market rather than cannibalizing injectables.
Green said West is participating in generic GLP-1 rollouts in several countries and is encouraged by next-generation GLP-1 molecules in development for obesity, diabetes and other metabolic conditions.
Margins expand as mix shifts toward proprietary products McMahon said total company gross margin was 37.7%, up 200 basis points from the prior year. Adjusted operating margin rose 230 basis points to 22.6%. The improvement was driven by stronger sales, positive mix shift toward HVP components, pricing and leverage across selling, general and administrative expenses and research and development, he said.
Price contributed four percentage points of revenue growth in the quarter. McMahon said pricing accelerated from the first quarter and was above the company’s 2% to 3% corridor, reflecting West’s effort to capture more of the value it provides to customers.
The West Vantage segment generated $150 million in revenue and grew 0.8% organically. McMahon said the segment was affected by the cyber incident, which pushed some revenue into the second half of the year. He estimated the impact at a mid-single-digit headwind to growth in the quarter and said the company expects to recover that revenue during the remainder of the year.
West reported $124 million in operating cash flow for the quarter. Capital expenditures were $43 million, down from $75 million in the prior year. The company repurchased just over 0.5 million shares for $157 million in the quarter and paid $16 million in dividends.
Company raises full-year outlook West now expects full-year 2026 revenue of $3.345 billion to $3.38 billion, representing 10% to 11% organic growth, up from its previous 7% to 9% organic growth forecast. Reported growth is expected to be 8.8% to 10%.
The company raised its adjusted EPS outlook to $8.85 to $9.05, implying year-over-year growth of 21% to 24%. McMahon said the updated outlook incorporates a stronger dollar, with currency now expected to provide a 1 percentage point tailwind, down from a prior assumption of about 2 percentage points.
West also completed the sale and transfer of manufacturing and supply rights for the SmartDose 3.5mL on-body delivery system and associated facilities on July 1. McMahon said the company excluded SmartDose 3.5 revenue from organic growth calculations for the year. He also said the divestiture is expected to contribute 50 basis points of margin improvement for the full year, or 100 basis points in the second half.
For the third quarter, West expects revenue of $820 million to $835 million, reflecting reported growth of 1.9% to 3.8% and organic growth of 7% to 8.9%. Adjusted diluted EPS is expected to be $2.14 to $2.24, up 9% to 14% year over year.
Leadership transition ahead Green, who is preparing to hand leadership to Michel Lagarde on Aug. 31, used his closing remarks to thank employees, customers, shareholders and the board. He said the quarter reaffirmed that West’s growth strategy is working and that the company remains focused on biologics, GLP-1s, Annex 1 and other HVP conversions.
“We have a durable business with a strong competitive moat, which delivers unique value to our customers,” Green said.
About West Pharmaceutical Services (NYSE:WST)West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.
In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in West Pharmaceutical Services Right Now?Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Key Takeaways West Pharmaceutical beat Q2 earnings and revenue estimates as high-value products drove growth.WST raised its 2026 EPS outlook after strong Proprietary Products and HVP performance.WST shares jumped pre-market as margins expanded and revenues grew across key product lines. West Pharmaceutical Services, Inc. (WST - Free Report) delivered adjusted second-quarter 2026 earnings per share (EPS) of $2.37, which moved up 28.8% year over year. The figure topped the Zacks Consensus Estimate by 13.9%.
The adjustments include expenses related to the amortization of acquisition-related intangible assets, among others.
GAAP EPS for the quarter was $2.15, reflecting an improvement of 18.1% from the year-ago figure.
WST’s Q2 Revenues in DetailWest Pharmaceutical registered revenues of $872.3 million, up 13.8% year over year. The figure surpassed the Zacks Consensus Estimate by 4.2%.
Organic net sales, which exclude the impact of acquisitions and/or divestitures, were up 12.7% year over year.
Robust performance by the Proprietary Products segment, along with continued growth in West Vantage (previously known as Contract-Manufactured Products) segment, drove the top-line improvement.
Shares of WST were up approximately 6% in today’s pre-market trading. The company’s shares have gained 30.2% in the year-to-date period against the industry’s 0.7% decline. The S&P 500 Index has risen 9.5% in the same time frame.
Image Source: Zacks Investment Research
West Pharmaceutical’s Segment DetailsWST operates under two segments: Proprietary Products and West Vantage.
In the quarter under review, Proprietary Products reported worldwide revenues of $722.6 million, up 16.6% year over year on a reported basis. Our estimate for the segment’s revenues was pinned at $680.3 million.
On an organic basis, revenues were up 15.5% year over year.
The segment’s high-value product (HVP) accounted for 49% of its net sales during the period. Sales of HVP components were up 19.4%, driven by strength in Westar and NovaPure products. HVP Delivery Devices, which represented 15% of total company net sales, increased 29.6%. The growth was primarily driven by the increased sales of self-injection device platforms and Daikyo Crystal Zenith. Standard Products, 19% of total company sales, increased 2.4%.
Revenues in the West Vantage segment totaled $149.7 million, up 2% year over year on a reported basis. This growth was driven by an increase in sales of self-injection devices for obesity and diabetes. Our estimate for this segment’s quarterly revenues was pegged at $152.4 million.
Organically, revenues were up 0.8% year over year.
WST’s Margin AnalysisIn the quarter under review, West Pharmaceutical’s gross profit increased 20.2% year over year to $329.2 million. The gross margin expanded approximately 200 basis points (bps) to 37.7%. We had projected a 36% gross margin for the second quarter of 2026.
Selling, general and administrative expenses increased 22.6% year over year to $117.6 million. Research and development expenses increased 3.1% to $19.7 million.
Adjusted operating profit totaled $197.4 million, reflecting a 27.1% improvement from the year-ago quarter’s level. The adjusted operating margin expanded 230 bps to 22.6%. We had projected a 20.6% operating margin for the quarter.
West Pharmaceutical’s Financial PositionWST exited the second quarter with cash and cash equivalents of $435.8 million compared with $521.4 million as of the end of the first quarter. Total debt was $202.8 million compared with $202.9 million at the end of the first quarter.
Cumulative net cash provided by continuing operating activities at the end of the second quarter was $213.9 million compared with $306.5 million a year ago.
West Pharmaceutical has a consistent dividend-paying history, with a five-year annualized dividend growth rate of 5.26%.
WST’s Guidance for Q3 & 2026West Pharmaceutical has issued third-quarter guidance and updated its financial outlook for 2026.
WST expects its third-quarter sales to be in the range of $820-$835 million, implying organic growth of 7-8.9%. The company expects EPS to be in the range of $2.14-$2.24. The Zacks Consensus Estimate for third-quarter sales and EPS is pegged at $817 million and $2.14, respectively.
WST projects full-year revenues to be between $3.345 billion and $3.380 billion (up from its previous guidance of $3.295 billion to $3.350 billion). Full-year revenues include a 1% benefit based on current foreign exchange rates. The Zacks Consensus Estimate is pegged at $3.33 billion.
For 2026, organic net sales are expected to grow 10-11% from the prior-year level.
For the full year, adjusted EPS is now anticipated to be in the range of $8.85-$9.05 (up from the previous guidance of $8.40-$8.75). The Zacks Consensus Estimate is pegged at $8.60.
HVP Momentum & Execution Strength Drives 2026 PerformanceWest Pharmaceutical exited the second quarter of 2026 with robust results. Solid top-line results, along with improvements in organic revenues, were impressive. Robust performance by the Proprietary Products segment was encouraging. Strength in HVP and upside growth in the Biologics, Pharma and Generics market units during the reported quarter were also promising. Gross margin and adjusted operating margin expansion bode well for the stock. Improving organic revenue trends reinforce confidence in the company’s execution capabilities.
WST reported a strong first half of 2026, with revenues and adjusted EPS exceeding expectations in the first two quarters. Performance was driven by the HVP Components business, which delivered double-digit growth across both GLP-1 and non-GLP-1 segments. The better-than-expected results can be attributed to sustained market demand and effective execution in scaling production capacity, particularly in Europe. Given the strong first-quarter performance and continued business momentum, management has raised its full-year 2026 guidance, signaling confidence in the company’s growth trajectory.
Management’s 2026 higher sales and EPS outlook suggests steady demand fundamentals, favorable currency tailwinds and portfolio optimization initiatives, including the planned SmartDose divestiture.
West Pharmaceutical’s Zacks Rank & Other Stocks to ConsiderWST currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are McKesson (MCK - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .
McKesson, carries a Zacks Rank #2 at present, has an estimated long-term growth rate of 13.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.09%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Globus Medical’s shares have gained 8.8% against the industry’s 12.7% decline in the year-to-date period.
Phibro Animal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.5%. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.25%.
Phibro Animal Health stock has climbed 44.2% against the industry’s 17.1% decline in the year-to-date period.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.
Cardinal Health’s shares have lost 2.6% compared with the industry’s 3.1% decline in the year-to-date period.
For the quarter ended June 2026, West Pharmaceutical Services (WST - Free Report) reported revenue of $872.3 million, up 13.8% over the same period last year. EPS came in at $2.37, compared to $1.84 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $836.8 million, representing a surprise of +4.24%. The company delivered an EPS surprise of +13.94%, with the consensus EPS estimate being $2.08.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how West Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Change in Organic Revenue: 12.7% versus 9.3% estimated by two analysts on average.Net Sales- Proprietary Products: $722.6 million versus the three-analyst average estimate of $688.29 million. The reported number represents a year-over-year change of +16.6%.Gross Profit- Proprietary Products: $308 million versus the three-analyst average estimate of $279.06 million.View all Key Company Metrics for West Pharmaceutical here>>>
Shares of West Pharmaceutical have returned +5.3% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Net sales of $872.3 million increased 13.8% year over year, with organic growth of 12.7%, beating the consensus of $838.586 million.
HVP Products And GLP-1 Demand Drive GrowthProprietary Products sales of $722.6 million grew by 16.6% and increased 15.5% on an organic basis.
High-Value Product (HVP) Components net sales of $424.1 million increased 19.4% and rose 18.4% on an organic basis.
During the earnings call, CEO Eric Green said, “This was driven by our three growth drivers, which include biologics and biosimilars, HVP upgrades including Annex 1, and continued strength in GLP-1 elastomers. We continue to believe in the near- and long-term growth prospects of HVP components.”
HVP Delivery Devices net sales of $131.2 million increased by 29.6% (+29.2%). Standard Products net sales of $167.3 million increased by 2.4% (+0.7%).
West Vantage Segment (Contract-Manufactured Products) sales reached $149.7 million, up 2% (+0.8%), slightly below expectations due to the impact of the cyber incident.
West Raises 2026 Guidance“As a result of our team’s strong execution in the second quarter and improved outlook, we are increasing our full-year 2026 guidance,” commented Eric Green.
West Pharmaceutical raised its fiscal 2026 adjusted earnings per share guidance from $8.40-$8.75 to $8.85-$9.05 compared to the consensus of $8.61.
The company revised 2026 sales guidance from $3.29 billion-$3.35 billion to $3.345 billion-$3.380 billion versus the Wall Street estimate of $3.332 billion.
West Pharmaceutical expects third quarter adjusted earnings of $2.14-$2.24 per share versus consensus of $2.12.
The company sees sales between $820 million and $835 million versus the consensus of $815.71 million.
Broader HVP Growth Despite Cost PressuresCFO Robert (Bob) McMahon said increased guidance is driven by higher growth expectations for the non-GLP-1 portion of HVP components as well as an increase in HVP delivery devices.
The company anticipates both GLP-1 and non-GLP-1 HVP components are now expected to grow in the high teens for the year.
From a margin perspective, West Pharma is experiencing some inflationary pressure from higher oil and commodity prices, and it is working to offset those costs.
WST Stock Price Activity: West Pharmaceutical shares were down 1.13% at $385.01 at the time of publication on Thursday, according to Benzinga Pro data.
Image Via Shutterstock
Market News and Data brought to you by Benzinga APIs
West Pharmaceutical Services, Inc. (WST) Q2 2026 Earnings Call July 23, 2026 8:00 AM EDT
Company Participants
John Sweeney - Vice President of Investor Relations
Eric Green - Non-Independent Chair of the Board, President & CEO
Robert McMahon - Senior VP & CFO
Conference Call Participants
Michael Ryskin - BofA Securities, Research Division
Paul Knight - KeyBanc Capital Markets Inc., Research Division
Patrick Donnelly - Citigroup Inc., Research Division
Matthew Larew - William Blair & Company L.L.C., Research Division
David Windley - Jefferies LLC, Research Division
Kallum Titchmarsh - Morgan Stanley, Research Division
Daniel Markowitz - Evercore ISI Institutional Equities, Research Division
Justin Bowers - Deutsche Bank AG, Research Division
Michael Polark - Wolfe Research, LLC
Steven Etoch - Stephens Inc., Research Division
Presentation
Operator
Good day, and welcome to the West Pharmaceutical Services Q2 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker, Mr. John Sweeney, Vice President of Investor Relations. Please go ahead, sir.
John Sweeney
Vice President of Investor Relations
Good morning, and welcome to West's Second Quarter 2026 Earnings Conference Call, which is being webcast live today. With me on the call are Eric Green, our CEO, Chair of the Board; and Bob McMahon, CFO.
Earlier today, we issued our second quarter financial results, a copy of the press release, along with today's slide presentation containing supplemental information for your reference has been posted in the Investors section of the company's website at investor.westpharma.com. Later today, a replay of the webcast will also be available in the Investors section of our website.
Before we begin, we'd like to remind you that statements made by management during this call and in the accompanying presentation contain forward-looking statements within the meaning of U.S. Federal Securities Law. Please refer to the accompanying safe
West Pharmaceutical Services (WST - Free Report) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $2.08 per share. This compares to earnings of $1.84 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +13.94%. A quarter ago, it was expected that this medical device company would post earnings of $1.68 per share when it actually produced earnings of $2.13, delivering a surprise of +26.79%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
West Pharmaceutical, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $872.3 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 4.24%. This compares to year-ago revenues of $766.5 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
West Pharmaceutical shares have added about 30.3% since the beginning of the year versus the S&P 500's gain of 9.6%.
What's Next for West Pharmaceutical?While West Pharmaceutical has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for West Pharmaceutical was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.14 on $816.95 million in revenues for the coming quarter and $8.60 on $3.33 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Cardinal Health (CAH - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 11.
This prescription drug distributor is expected to post quarterly earnings of $2.42 per share in its upcoming report, which represents a year-over-year change of +16.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Cardinal Health's revenues are expected to be $65.61 billion, up 9.1% from the year-ago quarter.
, /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the second quarter of 2026.
Second-Quarter Summary (comparisons to prior-year period)
Net sales of $872.3 million increased 13.8%; organic growth was 12.7%. Diluted earnings per share ("EPS") of $2.15 increased 18.1%. Adjusted-diluted EPS of $2.37 increased 28.8%. Operating cash flow was $213.9 million. Capital expenditures were $85.9 million. Free cash flow (defined as operating cash flow less capital expenditures) was $128.0 million. During the first six months of 2026, the Company repurchased 1.8 million shares for $454.3 million at an average price of $258.03 per share under its share repurchase program that was announced in mid-February 2026. The Company also announced on July 21, 2026 that its Board of Directors declared a third-quarter 2026 dividend of $0.22 per share. Outlook for Full-Year and Third-Quarter 2026
Full-year 2026 net sales are expected to be in the range of $3.345 billion to $3.380 billion, up 8.8% to 10.0% reported and up 10.0% to 11.0% organic. Full-year 2026 adjusted-diluted EPS guidance increased to a range of $8.85 to $9.05. Third-quarter 2026 net sales are expected to be in the range of $820 million to $835 million, up 1.9% to 3.8% reported and up 7.0% to 8.9% organic. Third-quarter 2026 adjusted-diluted EPS guidance is expected to be in the range of $2.14 to $2.24. Eric M. Green, President, Chief Executive Officer and Chair of the Board, commented: "I am pleased to report strong second-quarter results, with net sales and adjusted EPS exceeding our expectations. Net sales increased 12.7% organically, driven by our High Value Product Components business which benefited from continued strength in Biologics, a favorable mix shift from HVP upgrades including Annex 1, and ongoing growth in GLP-1 elastomers. The robust sales growth drove strong operating income margin expansion as compared to prior year. As a result of our team's strong execution in the second quarter and improved outlook, we are increasing our full-year 2026 guidance."
Proprietary Products Segment
Net sales of $722.6 million grew by 16.6% and increased 15.5% on an organic basis.
High-Value Product ("HVP") Components net sales of $424.1 million increased 19.4% and rose 18.4% on an organic basis. HVP Components accounted for 49% of total company net sales in the quarter. HVP Delivery Devices net sales of $131.2 million increased by 29.6%, and were up 29.2% on an organic basis. HVP Delivery Devices accounted for 15% of total company net sales in the quarter. Standard Products net sales of $167.3 million increased by 2.4% and rose 0.7% on an organic basis. Standard Products accounted for 19% of total company net sales this quarter. West Vantage Segment
Net sales of $149.7 million increased by 2.0% and rose 0.8% on an organic basis. West Vantage accounted for 17% of total company net sales in the quarter.
Full-Year 2026 Financial Guidance
The Company is increasing its full-year 2026 net sales guidance range to $3.345 billion to $3.380 billion, up from $3.295 billion to $3.350 billion. Reported net sales growth is anticipated to be in the range of 8.8% to 10.0%, and organic net sales growth is expected to be in the range of 10.0% to 11.0%. Net sales guidance includes an estimated full-year 2026 benefit of approximately 1 percentage point based on current foreign currency exchange rates. SmartDose® 3.5mL generated $55 million in net sales in the second half of 2025. These net sales are excluded going forward to calculate our organic net sales growth guidance. The Company is increasing its full-year 2026 adjusted-diluted EPS guidance range to $8.85 to $9.05, up from the previous range of $8.40 to $8.75. Capital spending guidance is unchanged from a range of $250 million to $275 million. Third-Quarter 2026 Financial Guidance
The Company is introducing its third-quarter 2026 net sales guidance range of $820 million to $835 million. Reported net sales growth is anticipated to be in the range of 1.9% to 3.8%, and organic net sales growth is expected to be in the range of 7.0% to 8.9%. Net sales guidance includes an estimated headwind of approximately 1 percentage point based on current foreign currency exchange rates. SmartDose® 3.5mL generated $30 million in net sales in the third quarter of 2025. These net sales are excluded going forward to calculate our organic net sales growth guidance. The Company is introducing its third-quarter 2026 adjusted-diluted EPS guidance range of $2.14 to $2.24. Second-Quarter 2026 Conference Call
Management will host a conference call at 8 a.m. EDT today. The live webcast can be accessed in the "Investors" section of the Company's website by clicking here.
To participate in the Q&A portion of the conference call, please register in advance by clicking here.
Registered telephone participants will receive the dial-in number along with a unique PIN number that will enable them to ask questions on the call.
An accompanying slide presentation will be posted in the "Investors" section of the Company's website.
A replay of the webcast will be available on the Company's website for approximately 90 days after the event.
About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 26 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.
Daikyo®, Daikyo Crystal Zenith® and Daikyo CZ® are registered trademarks of Daikyo Seiko, Ltd. Daikyo Crystal Zenith technologies are licensed from Daikyo Seiko, Ltd.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the Company's expectations regarding future events, financial guidance and financial or operational performance. Forward-looking statements may be identified by words such as "believe," "expect," "intend," "estimate," "plan," "anticipate," "project," "forecast," "guidance," "target," "may," "will," "continue" and similar expressions.
These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. For additional information regarding these risks as well as other risks, uncertainties and factors that could affect our forward-looking statements, please refer to Part I Item 1A, entitled "Risk Factors," of the Company's most recent Annual Report on Form 10-K and any amendments thereto, as well as the Company's most recently filed Quarterly Reports on Form 10-Q and other filings the Company makes with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date of this press release. Except as required by law or regulation, West Pharmaceutical Services, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Non-U.S. GAAP Financial Measures
The Company reports its financial results in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). However, management also uses certain non-U.S. GAAP financial measures in evaluating our results of operations. Management believes that this information provides users with a valuable insight into our overall performance and financial position. As a result, this release contains certain non-GAAP financial measures, including organic net sales, adjusted-diluted EPS and adjusted operating profit. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign currency exchange rates in effect during the comparable prior-year period. We may also refer to financial results, such as adjusted-diluted EPS and adjusted operating profit, that exclude the effects of unallocated items. The unallocated items are not representative of ongoing operations, and generally include restructuring and related charges, certain asset impairments, and other specifically identified income or expense items. These non-U.S. GAAP financial measures should be viewed in addition to, and not as an alternative for, the Company's results prepared in accordance with U.S. GAAP. A reconciliation of these non-U.S. GAAP measures to the comparable U.S. GAAP financial measures is included in the accompanying tables.
WEST PHARMACEUTICAL SERVICES, INC.
CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
(in millions, except per share data)
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
Net sales
$ 872.3
100 %
$ 766.5
100 %
$ 1,717.2
100 %
$ 1,464.5
100 %
Cost of goods and services sold
543.1
62
492.6
64
1,091.6
64
958.7
65
Gross profit
329.2
38
273.9
36
625.6
36
505.8
35
Research and development
19.7
2
19.1
2
35.5
2
35.4
2
Selling, general and administrative expenses
117.6
14
95.9
13
217.1
12
183.9
13
Other expense (income), net
12.8
1
5.2
1
16.8
1
25.8
2
Operating profit
179.1
21
153.7
20
356.2
21
260.7
18
Interest (income) expense, net
(1.2)
—
(3.5)
—
(4.4)
—
(7.2)
—
Other nonoperating expense (income)
0.2
—
0.2
—
0.4
—
0.4
—
Income before income taxes and equity
in net income of affiliated companies
180.1
21
157.0
20
360.2
21
267.5
18
Income tax expense
32.2
4
30.2
4
76.9
4
54.3
4
Equity in net income of affiliated companies
(6.1)
(1)
(5.0)
(1)
(9.5)
—
(8.4)
(1)
Net income
$ 154.0
18 %
$ 131.8
17 %
$ 292.8
17 %
$ 221.6
15 %
Net income per share:
Basic
$ 2.17
$ 1.82
$ 4.10
$ 3.06
Diluted
$ 2.15
$ 1.82
$ 4.07
$ 3.05
Average common shares outstanding
70.8
72.2
71.4
72.3
Average shares assuming dilution
71.3
72.5
71.9
72.8
WEST PHARMACEUTICAL SERVICES
REPORTING SEGMENT INFORMATION
(UNAUDITED)
(in millions)
Three Months Ended
June 30,
Six Months Ended
June 30,
Net Sales:
2026
2025
2026
2025
Proprietary Products
$ 722.6
$ 619.8
$ 1,416.9
$ 1,182.8
West Vantage
149.7
146.7
300.3
281.7
Consolidated Total
$ 872.3
$ 766.5
$ 1,717.2
$ 1,464.5
Gross Profit:
Proprietary Products
$ 308.0
$ 248.3
$ 581.1
$ 458.5
West Vantage
21.2
25.6
44.5
47.3
Gross Profit
$ 329.2
$ 273.9
$ 625.6
$ 505.8
Gross Profit Margin
37.7 %
35.7 %
36.4 %
34.5 %
Operating Profit (Loss):
Proprietary Products
$ 211.9
$ 161.7
$ 401.1
$ 292.3
West Vantage
12.9
17.8
28.5
31.3
Stock-based compensation expense
(10.9)
(7.4)
(17.5)
(8.7)
General corporate costs
(34.8)
(18.4)
(55.9)
(54.2)
Reported Operating Profit
$ 179.1
$ 153.7
$ 356.2
$ 260.7
Reported Operating Profit Margin
20.5 %
20.1 %
20.7 %
17.8 %
Unallocated items
18.3
1.6
22.2
19.6
Adjusted Operating Profit
$ 197.4
$ 155.3
$ 378.4
$ 280.3
Adjusted Operating Profit Margin
22.6 %
20.3 %
22.0 %
19.1 %
WEST PHARMACEUTICAL SERVICES
RECONCILIATION OF NON-U.S. GAAP MEASURES (UNAUDITED)
Please refer to "Non-U.S. GAAP Financial Measures" for more information
(in millions, except per share data)
Reconciliation of Reported and Adjusted Operating Profit, Net Income and Diluted EPS
Three Months ended June 30, 2026
Operating
profit
Income
tax
expense
Net
income
Diluted
EPS
Reported (U.S. GAAP)
$179.1
$32.2
$154.0
$2.15
Unallocated Items:
Restructuring and other charges(1)
1.5
0.3
1.2
0.02
M&A activities, including SmartDose® 3.5mL sale(2)
6.4
1.5
4.9
0.07
Cost-method investment activity(3)
3.5
—
3.5
0.05
Amortization of acquisition-related intangible assets(4)
—
—
0.4
—
Other(5)
6.9
1.4
5.4
0.08
Adjusted (Non-U.S. GAAP)
$197.4
$35.4
$169.4
$2.37
Six Months ended June 30, 2026
Operating
profit
Income
tax
expense
Net
income
Diluted
EPS
Reported (U.S. GAAP)
$356.2
$76.9
$292.8
$4.07
Unallocated Items:
Restructuring and other charges(1)
2.9
(11.3)
14.2
0.20
M&A activities, including SmartDose® 3.5mL sale(2)
8.3
1.9
6.4
0.09
Cost-method investment activity(3)
3.5
—
3.5
0.05
Amortization of acquisition-related intangible assets(4)
—
—
0.9
0.01
Other(5)
7.5
1.6
5.9
0.08
Adjusted (Non-U.S. GAAP)
$378.4
$69.1
$323.7
$4.50
Three Months ended June 30, 2025
Operating
profit
Income
tax
expense
Net
income
Diluted
EPS
Reported (U.S. GAAP)
$153.7
$30.2
$131.8
$1.82
Unallocated items:
Restructuring and other charges(1)
1.6
0.4
1.2
0.02
Amortization of acquisition-related intangible assets(4)
—
—
0.5
—
Adjusted (Non-U.S. GAAP)
$155.3
$30.6
$133.5
$1.84
Six Months ended June 30, 2025
Operating
profit
Income
tax
expense
Net
income
Diluted
EPS
Reported (U.S. GAAP)
$260.7
$54.3
$221.6
$3.05
Unallocated items:
Restructuring and other charges(1)
19.4
2.4
17.0
0.23
Amortization of acquisition-related intangible assets(4)
0.2
—
1.1
0.01
Adjusted (Non-U.S. GAAP)
$280.3
$56.7
$239.7
$3.29
(1)
During the three and six months ended June 30, 2026, the Company recorded pre-tax charges of $1.5 million and $2.9 million, respectively, related to our two existing restructuring programs: (i) $1.0 million and $1.9 million, respectively, within other expense (income), related to acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $0.5 million and $1.0 million, respectively, within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries. In addition, we recorded a one-time tax cost of $12.0 million associated with an internal legal entity restructuring which occurred in the first quarter of 2026. During the three and six months ended June 30, 2025, the Company recorded pre-tax charges of $1.6 million and $19.4 million, respectively, related to our two existing restructuring programs: (i) $0.2 million and $16.6 million, respectively, within other expense (income), related to severance, acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $1.4 million and $2.8 million, respectively, within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries. In addition, we recorded income tax charges of $2.0 million in the first quarter of 2025, related primarily to withholding tax and capital gains incurred in executing our plan to optimize our legal structure.
(2)
During the three and six months ended June 30, 2026, the Company recorded pre-tax charges of $6.4 million and $8.3 million, respectively, related to M&A activities, including the Company's agreement to sell its SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie. The Company recorded $1.3 million and $2.2 million, respectively, of the charges within other expense (income), related to employee benefit costs in connection with the sale agreement. The Company recorded the remaining $5.1 million and $6.1 million, respectively, within selling, general and administrative expenses, relating to professional services in connection with the sale agreement and other M&A activities.
(3)
During the three and six months ended June 30, 2026, the Company recorded cost-method investment impairment charges of $3.5 million within other expense (income).
(4)
During the three and six months ended June 30, 2026, the Company recorded $0.4 million and $0.9 million, respectively, of amortization expense in association with an acquisition of increased ownership interest in Daikyo. During the three and six months ended June 30, 2025, the Company recorded $0.0 million and $0.2 million, respectively, of amortization expense within selling, general and administrative expenses associated with an intangible asset acquired during the second quarter of 2020. During the three and six months ended June 30, 2025, the Company recorded $0.5 million and $0.9 million, respectively, of amortization expense in association with an acquisition of increased ownership interest in Daikyo.
(5)
Other includes nonrecurring professional fees associated with various items including certain legal matters and our cybersecurity incident from May 2026. These charges are recorded within selling, general and administrative expenses.
WEST PHARMACEUTICAL SERVICES
RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED)
Please refer to "Non-U.S. GAAP Financial Measures" for more information
(in millions, except per share data)
Reconciliation of Reported Net Sales to Organic Net Sales by Segment (6)
Three Months Ended
June 30,
Reported Net Sales
(U.S. GAAP)
Percent
Change
Impact of
Currency
Organic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (6)
2026
2025
Proprietary Products
$722.6
$619.8
16.6 %
1.1 %
15.5 %
West Vantage
149.7
146.7
2.0 %
1.2 %
0.8 %
Total
$872.3
$766.5
13.8 %
1.1 %
12.7 %
Six Months Ended
June 30,
Reported Net Sales
(U.S. GAAP)
Percent
Change
Impact of
Currency
Organic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (6)
2026
2025
Proprietary Products
$1,416.9
$1,182.8
19.8 %
3.3 %
16.5 %
West Vantage
300.3
281.7
6.6 %
3.2 %
3.4 %
Total
$1,717.2
$1,464.5
17.3 %
3.4 %
13.9 %
Reconciliation of Proprietary Products Segment Organic Net Sales by Product Category (6)
Three Months Ended
June 30,
Reported Net Sales
(U.S. GAAP)
Percent
Change
Impact of
Currency
Organic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (6)
2026
2025
HVP Components
$424.1
$355.2
19.4 %
1.0 %
18.4 %
HVP Delivery Devices
131.2
101.2
29.6 %
0.4 %
29.2 %
Standard Products
167.3
163.4
2.4 %
1.7 %
0.7 %
Total Proprietary Products
$722.6
$619.8
16.6 %
1.1 %
15.5 %
Six Months Ended
June 30,
Reported Net Sales
(U.S. GAAP)
Percent
Change
Impact of
Currency
Organic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (6)
2026
2025
HVP Components
$833.4
$671.1
24.2 %
3.8 %
20.4 %
HVP Delivery Devices
254.8
197.0
29.3 %
1.0 %
28.3 %
Standard Products
328.7
314.7
4.4 %
3.8 %
0.6 %
Total Proprietary Products
$1,416.9
$1,182.8
19.8 %
3.3 %
16.5 %
Reconciliation of Proprietary Products Segment Organic Net Sales by Market Group (6)
Three Months Ended
June 30,
Reported Net Sales
(U.S. GAAP)
Percent
Change
Impact of
Currency
Organic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (6)
2026
2025
Biologics
$374.8
$287.7
30.3 %
1.1 %
29.2 %
Pharma
205.0
198.5
3.3 %
1.7 %
1.6 %
Generics
142.8
133.6
6.9 %
0.2 %
6.7 %
Total Proprietary Products
$722.6
$619.8
16.6 %
1.1 %
15.5 %
Six Months Ended
June 30,
Reported Net Sales
(U.S. GAAP)
Percent
Change
Impact of
Currency
Organic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (6)
2026
2025
Biologics
$729.3
$557.0
30.9 %
3.3 %
27.6 %
Pharma
415.6
379.1
9.6 %
4.1 %
5.5 %
Generics
272.0
246.7
10.3 %
2.2 %
8.1 %
Total Proprietary Products
$1,416.9
$1,182.8
19.8 %
3.3 %
16.5 %
Reconciliation of Reported Net Sales to Organic Net Sales by Geography (6)
Three Months Ended
June 30,
Reported Net Sales
(U.S. GAAP)
Percent
Change
Impact of
Currency
Organic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (6)
2026
2025
Americas
$388.7
$349.7
11.2 %
0.6 %
10.6 %
Europe, Middle East, Africa
399.8
349.7
14.3 %
2.2 %
12.1 %
Asia Pacific
83.8
67.1
24.9 %
(2.1) %
27.0 %
Total
$872.3
$766.5
13.8 %
1.1 %
12.7 %
Six Months Ended
June 30,
Reported Net Sales
(U.S. GAAP)
Percent
Change
Impact of
Currency
Organic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (6)
2026
2025
Americas
$766.0
$688.6
11.2 %
0.5 %
10.7 %
Europe, Middle East, Africa
799.2
656.6
21.7 %
6.9 %
14.8 %
Asia Pacific
152.0
119.3
27.4 %
(0.6) %
28.0 %
Total
$1,717.2
$1,464.5
17.3 %
3.4 %
13.9 %
(6)
Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign currency exchange rates in effect during the comparable prior-year period.
WEST PHARMACEUTICAL SERVICES
RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED)
Please refer to "Non-U.S. GAAP Financial Measures" for more information
(in millions, except per share data)
Reconciliation of Reported-Diluted EPS Guidance to Adjusted-Diluted EPS Guidance
2025 Actual
2026 Guidance
% Change
Reported-diluted EPS (U.S. GAAP)
$6.79
$9.01 to $9.26
32.7% to 36.4%
Restructuring and other charges
0.31
0.23
M&A activities, including SmartDose® 3.5mL sale
0.09
(0.54) to (0.59)
Cost-method investment activity
0.06
0.05
Amortization of acquisition-related intangible assets
0.03
0.02
Other
0.01
0.08
Adjusted-diluted EPS (Non-U.S. GAAP)
$7.29
$8.85 to $9.05
21.4% to 24.1%
WEST PHARMACEUTICAL SERVICES
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(in millions, except per share data)
June 30,
2026
December 31,
2025
ASSETS
Current assets:
Cash and cash equivalents
$ 435.8
$ 791.3
Accounts receivable, net
712.0
574.4
Inventories
447.4
443.9
Other current assets
212.3
168.6
Total current assets
1,807.5
1,978.2
Property, plant and equipment
3,248.6
3,223.4
Less: accumulated depreciation and amortization
1,562.3
1,497.0
Property, plant and equipment, net
1,686.3
1,726.4
Operating lease right-of-use assets
104.7
117.0
Investments in affiliated companies
207.7
212.3
Goodwill
108.7
109.9
Intangible assets, net
6.4
7.7
Deferred income taxes
72.3
38.4
Other noncurrent assets
82.8
80.1
Total Assets
$ 4,076.4
$ 4,270.0
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable
$ 252.7
$ 253.7
Accrued salaries, wages and benefits
97.1
135.9
Income taxes payable
64.7
28.1
Operating lease liabilities
20.9
22.7
Accrued commissions, rebates and royalties
34.0
39.2
Other current liabilities
171.1
175.3
Total current liabilities
640.5
654.9
Long-term debt
202.9
202.8
Deferred income taxes
22.4
23.0
Pension and other postretirement benefits
28.3
29.0
Operating lease liabilities
88.3
95.6
Deferred compensation benefits
13.9
13.5
Other long-term liabilities
89.9
75.2
Total Liabilities
1,086.2
1,094.0
Equity:
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding
—
—
Common stock, par value $0.25 per share; 200.0 million shares authorized; shares
issued: June 30, 2026 - 75.3 million, December 31, 2025 - 75.3 million; shares
outstanding: June 30, 2026 - 70.4 million, December 31, 2025 - 72.0 million
18.8
18.8
Capital in excess of par value
—
—
Retained earnings
4,624.1
4,374.9
Accumulated other comprehensive loss
(140.4)
(105.5)
Treasury stock, at cost (June 30, 2026 - 4.9 million shares, December 31, 2025 -
3.3 million shares)
(1,512.3)
(1,112.2)
Total Equity
2,990.2
3,176.0
Total Liabilities and Equity
$ 4,076.4
$ 4,270.0
WEST PHARMACEUTICAL SERVICES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(in millions)
Six Months Ended
June 30,
2026
2025
Cash flows from operating activities:
Net income
$ 292.8
$ 221.6
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation
90.3
79.9
Amortization
1.1
1.5
Stock-based compensation
17.5
8.7
Non-cash restructuring charges
1.9
1.6
Asset impairments
4.2
4.1
Other non-cash items, net
(5.0)
(6.9)
Changes in assets and liabilities
(188.9)
(4.0)
Net cash provided by operating activities
213.9
306.5
Cash flows from investing activities:
Capital expenditures
(85.9)
(146.5)
Net cash used in investing activities
(85.9)
(146.5)
Cash flows from financing activities:
Borrowings under revolving credit agreements
50.0
—
Repayments under revolving credit agreements
(50.0)
—
Principal repayments on finance leases
(0.7)
(0.5)
Excise tax payments
(0.8)
(4.2)
Dividend payments
(31.5)
(30.3)
Proceeds from stock-based compensation awards
12.4
6.0
Employee stock purchase plan contributions
3.9
3.6
Shares purchased under share repurchase programs
(454.3)
(134.0)
Shares repurchased for employee tax withholdings
(2.5)
(2.5)
Net cash used in financing activities
(473.5)
(161.9)
Effect of exchange rates on cash
(10.0)
27.0
Net decrease in cash and cash equivalents
(355.5)
25.1
Cash, including cash equivalents at beginning of period
CompaniesJuly 23 (Reuters) - West Pharmaceutical Services (WST.N), opens new tab raised its annual profit and revenue forecasts on Thursday as strong demand for components used in injectable drugs, including diabetes and obesity treatments, helped it beat second-quarter estimates.
Here are the details:
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
West Pharma makes components such as stoppers, plungers and delivery systems used to package and administer vaccines, biologics and other injectable drugs.
Medical equipment makers such as West Pharma have benefited from surging demand for diabetes and obesity drugs such as Novo Nordisk's (NOVOb.CO), opens new tab Ozempic and Wegovy and Eli Lilly's (LLY.N), opens new tab Mounjaro, which rely on injection pens to deliver the therapies.
In May, West Pharma said it had restored operations across its sites after a cybersecurity attack and expects the incident to have no material impact on its 2026 financial outlook.
The Pennsylvania-based company reported second-quarter adjusted profit of $2.37 per share, above analysts' estimate of $2.08 per share, according to LSEG data.
Its quarterly revenue came in at $872.3 million, above analysts' expectations of $838.6 million.
Revenue in its proprietary products unit came in at $722.6 million, beating analysts' average estimate of $688.8 million. The segment makes up more than half of the company's total revenues.
West Pharma now expects 2026 adjusted profit per share to be between $8.85 and $9.05, compared to prior view of $8.40 to $8.75 per share.
The company expects its annual sales to be in the range of $3.35 billion to $3.38 billion, up from its previous forecast of between $3.295 billion and $3.35 billion.
It expects third-quarter profit to be in the range of $2.14 to $2.24 per share, compared with estimates of $2.12.
Reporting by Siddhi Mahatole in Bengaluru
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Andra AP fonden grew its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 723.5% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 55,007 shares of the medical instruments supplier’s stock after buying an additional 48,327 shares during the period. Andra AP fonden owned approximately 0.08% of West Pharmaceutical Services worth $13,787,000 as of its most recent filing with the SEC.
Other hedge funds have also made changes to their positions in the company. Elyxium Wealth LLC acquired a new position in shares of West Pharmaceutical Services in the 4th quarter valued at $25,000. CYBER HORNET ETFs LLC bought a new stake in West Pharmaceutical Services in the second quarter valued at about $25,000. Cornerstone Planning Group LLC increased its stake in West Pharmaceutical Services by 90.9% in the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 50 shares during the period. Bayban acquired a new position in West Pharmaceutical Services in the fourth quarter worth about $27,000. Finally, Private Trust Co. NA lifted its stake in West Pharmaceutical Services by 156.4% during the fourth quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 61 shares during the period. Institutional investors own 93.90% of the company’s stock.
West Pharmaceutical Services Stock Performance WST stock opened at $359.32 on Wednesday. The company has a 50 day moving average price of $334.27 and a 200 day moving average price of $286.00. West Pharmaceutical Services, Inc. has a fifty-two week low of $211.10 and a fifty-two week high of $367.66. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.71 and a quick ratio of 2.04. The stock has a market capitalization of $25.39 billion, a PE ratio of 48.04, a price-to-earnings-growth ratio of 2.85 and a beta of 1.16.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last announced its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.45. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The firm had revenue of $844.90 million during the quarter, compared to analysts’ expectations of $779.67 million. During the same period in the previous year, the business posted $1.45 EPS. The company’s quarterly revenue was up 21.0% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Analysts forecast that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current year.
Analysts Set New Price Targets A number of equities analysts have recently issued reports on the company. BNP Paribas Exane started coverage on West Pharmaceutical Services in a report on Monday, July 13th. They issued an “outperform” rating and a $447.00 target price for the company. Morgan Stanley boosted their price target on West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, April 27th. Zacks Research raised West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Finally, Citigroup reiterated a “buy” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $363.17.
Get Our Latest Stock Report on West Pharmaceutical Services
Insider Transactions at West Pharmaceutical Services In other West Pharmaceutical Services news, VP Annette F. Favorite sold 2,817 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the sale, the vice president owned 16,828 shares of the company’s stock, valued at approximately $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Chad Winters sold 896 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the transaction, the chief accounting officer directly owned 1,523 shares of the company’s stock, valued at $457,920.41. This trade represents a 37.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.60% of the company’s stock.
West Pharmaceutical Services Company Profile (Free Report)
West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.
In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.
Further Reading Five stocks we like better than West Pharmaceutical Services Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Free Report).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAndra AP fonden Buys Shares of 32,687 Seagate Technology Holdings PLC $STX
NEXT HEADLINE »Danaher Corporation $DHR Stake Raised by Andra AP fonden
, /PRNewswire/ -- On July 21, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on August 5, 2026 to shareholders of record on July 29, 2026.
About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life saving and life enhancing medicines for patients. With over 10,000 team members across 50 sites including 26 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.
Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.
Key Takeaways WST is expected to post 9.2% revenue growth and 13% higher EPS in the second quarter.West Pharmaceutical Services may benefit from strong biologics and GLP-1 component demand.WST's margins may gain from favorable product mix, pricing and manufacturing efficiencies. West Pharmaceutical Services (WST - Free Report) is scheduled to release second-quarter 2026 results on July 23, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 26.79%. WST’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.37%.
Q2 EstimatesPer management, the company expects first-quarter revenues to be in the range of $770-$790 million, implying 5-7% organic sales growth. Also, adjusted diluted earnings per share (EPS) are expected to be in the range of $1.65-$1.70.
Currently, the Zacks Consensus Estimate for revenues is pegged at $836.8 million, indicating growth of 9.2% year over year. The consensus mark for earnings is pinned at $2.08 per share, indicating an improvement of 13%.
Our model estimates total revenues to be $832.7 million, implying a 9.8% organic improvement year over year. The adjusted EPS is estimated to be $2.06. While the Proprietary Products segment sales are anticipated to be $680.3 million (organic growth of 11%), West Vantage (formerly Contract Manufacturing) segmental sales are likely to be $152.4 million (organic growth of 5.1%). Operating profit for the Proprietary Products segment is expected to increase 15.8%, while that for the West Vantage segment is projected to decline 4%.
Factors to NoteWest Pharmaceutical Services is expected to have delivered another solid quarterly performance, supported by sustained demand for high-value products (HVP), continued strength in biologics and GLP-1-related components, and favorable product mix. The company's recent commentary suggests that demand across both GLP-1 and non-GLP-1 markets might have remained healthy, aided by increasing biologics adoption, biosimilar launches and Annex 1-related conversions. Management also highlighted improving manufacturing productivity and capacity utilization across its European facilities, which likely supported higher output and operating leverage. Elevated oil, freight and commodity costs may have created some margin headwinds, although pricing actions, operational efficiencies and favorable product mix are expected to have largely offset these pressures.
Within the Proprietary Products segment, HVP Components are likely to have remained the primary growth engine. Demand from GLP-1 therapies should have stayed robust, supported by expanding patient adoption, broader reimbursement, new indications and continued injectable market growth. At the same time, non-GLP-1 HVP Components are expected to have benefited from strong biologics demand, increasing NovaPure adoption, biosimilar commercialization and continued customer migration toward higher-value products under Annex 1 compliance initiatives.
HVP Delivery Devices are also expected to have posted healthy growth, supported by SelfDose and Crystal Zenith, while SmartDose volumes likely remained elevated ahead of the planned divestiture. Standard Products, however, may have recorded only modest growth as ongoing customer conversions toward HVP Components continued to weigh on legacy product volumes.
West Vantage is expected to have delivered steady growth, supported by increasing demand for drug-handling services and self-injection devices used in obesity and diabetes therapies. However, the ongoing transition from the continuous glucose monitoring contract may have partially offset the benefit.
Earnings are likely to have benefited from favorable HVP mix, manufacturing efficiencies and pricing discipline. Continued operating leverage and disciplined capital spending should have supported earnings growth despite inflationary cost pressures, positioning the company for another quarter of healthy margin expansion and solid EPS performance.
Earnings Beat LikelyOur proven model predicts an earnings beat for WST this earnings season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat, which is the case here.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (earnings of $2.09 per share) and the Zacks Consensus Estimate, is +0.66%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks Worth a LookHere are some other medical product stocks worth considering, as these too have the right combination of elements to post an earnings beat this reporting cycle.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.41% and a Zacks Rank #2 at present.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 3.74%. The Zacks Consensus Estimate for HSIC’s second-quarter EPS indicates an improvement of 10.9% from the year-ago reported figure.
Alcon (ALC - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank of 2 at present. The company is set to release second-quarter 2026 results on August 10.
ALC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 3.66%. The Zacks Consensus Estimate for ALC’s second-quarter EPS implies an improvement of 1.3% from the year-ago reported figure.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank of 2 at present. The company is slated to release fourth-quarter fiscal 2026 results on Aug 11.
CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS reflects a gain 16.4% from the year-ago reported figure.
Wall Street analysts forecast that West Pharmaceutical Services (WST - Free Report) will report quarterly earnings of $2.08 per share in its upcoming release, pointing to a year-over-year increase of 13%. It is anticipated that revenues will amount to $836.8 million, exhibiting an increase of 9.2% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some West Pharmaceutical metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Net Sales- Contract-Manufactured Products' will likely reach $150.69 million. The estimate points to a change of +2.7% from the year-ago quarter.
Analysts expect 'Net Sales- Proprietary Products' to come in at $688.29 million. The estimate indicates a year-over-year change of +11.1%.
The consensus among analysts is that 'Change in Organic Revenue' will reach 9.3%. Compared to the current estimate, the company reported 6.8% in the same quarter of the previous year.
It is projected by analysts that the 'Gross Profit- Proprietary Products' will reach $279.06 million. The estimate compares to the year-ago value of $248.30 million.
The consensus estimate for 'Gross Profit- Contract-Manufactured Products' stands at $24.97 million. Compared to the present estimate, the company reported $25.60 million in the same quarter last year.
View all Key Company Metrics for West Pharmaceutical here>>>
Over the past month, West Pharmaceutical shares have recorded returns of +6.9% versus the Zacks S&P 500 composite's -0.6% change. Based on its Zacks Rank #1 (Strong Buy), WST will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Wall Street expects a year-over-year increase in earnings on higher revenues when West Pharmaceutical Services (WST - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 23. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis medical device company is expected to post quarterly earnings of $2.08 per share in its upcoming report, which represents a year-over-year change of +13%.
Revenues are expected to be $836.8 million, up 9.2% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.03% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for West Pharmaceutical?For West Pharmaceutical, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +0.66%.
On the other hand, the stock currently carries a Zacks Rank of #2.
So, this combination indicates that West Pharmaceutical will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that West Pharmaceutical would post earnings of $1.68 per share when it actually produced earnings of $2.13, delivering a surprise of +26.79%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
West Pharmaceutical appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Key Takeaways West Pharmaceutical is benefiting from strong HVP demand, GLP-1 programs and Annex 1 conversions.WST raised organic growth guidance as biologics, biosimilars and premium products gained momentum.West Pharmaceutical faces risks from GLP-1 concentration and qualification timelines that limit capacity. West Pharmaceutical Services, Inc. (WST - Free Report) is well positioned for growth, backed by strong demand for HVPs, expanding GLP-1 drug programs and regulatory-driven Annex 1 conversions. However, tariff impacts, destocking in generics and execution challenges at constrained European facilities are concerning.
Shares of this Zacks Rank #2 (Buy) company have gained 29.9% year to date against the industry's 0.7% decline. The S&P 500 Index has risen 9.7% in the same time frame.
West Pharmaceutical, with a market capitalization of $25.41 billion, is a leading global manufacturer engaged in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Its earnings are anticipated to improve 13.9% over the next five years. The company delivered a trailing four-quarter average earnings surprise of 19.37%.
Image Source: Zacks Investment Research
Positive Factors Driving WST’s ProspectsHigh-Value Product Components Continue to Drive Premium Growth: West Pharma's High-Value Product (HVP) Components business remains its strongest earnings driver, delivering 23% organic growth in the first quarter, supported by robust demand across both GLP-1 and non-GLP-1 applications. More than two-thirds of the quarterly outperformance came from non-GLP-1 products, indicating that growth is becoming increasingly diversified.
Biologics expanded 26%, while biosimilars, Annex 1 conversions and HVP upgrades continued to accelerate. This broad-based demand reduces reliance on any single therapeutic category and reinforces the company's transition toward a higher-margin product mix. Management's decision to raise full-year organic growth guidance to 7-9% reflects confidence that these structural growth drivers will remain intact beyond the current quarter.
Annex 1 Adoption Creates a Multi-Year Premiumization Opportunity: Regulatory changes under EU Annex 1 continue to represent one of West Pharma's most durable long-term growth catalysts. Management disclosed that Annex 1-related projects increased 66% year over year, with conversions now extending beyond Europe as pharmaceutical manufacturers increasingly standardize manufacturing processes globally.
The company expects Annex 1 and HVP conversion to contribute approximately 200 basis points to annual revenue growth in 2026 and believes the opportunity extends across at least 6 billion units targeted for conversion. Since these upgrades improve pricing and margins without requiring incremental market volume, the trend provides a structurally attractive earnings lever that should support sustained margin expansion for several years.
GLP-1 Market Expansion Continues to Provide Long-Term Demand Visibility: Management remains increasingly optimistic that GLP-1 therapies will remain a long-duration growth engine rather than a cyclical opportunity. GLP-1-related HVP Component sales represented 10% of total company revenues, while management reiterated that oral GLP-1 therapies are expanding — not replacing — the injectable market.
Additional growth drivers include broader insurance coverage, reduced drug prices, generic launches outside the United States and expanding indications beyond diabetes and obesity. The company also highlighted a growing pipeline of combination molecules and next-generation biologics, positioning West Pharma to benefit regardless of which manufacturers ultimately capture market share. This diversified exposure strengthens long-term revenue visibility across the injectable drug ecosystem.
Biologics and Biosimilars Are Strengthening Revenue Diversification: West Pharma continues to benefit from accelerating biologics commercialization, with the biologics business growing 26% organically during the first quarter. Growth is increasingly driven by commercialized therapies rather than speculative pipeline launches, providing greater earnings visibility.
Management highlighted strong momentum in NovaPure products, rising biosimilar launches and easing regulatory requirements that support broader therapy adoption. Biosimilar introductions often expand patient access instead of replacing branded therapies, allowing West Pharma to maintain or even increase elastomer demand. As pharmaceutical companies continue investing in biologics and biosimilars worldwide, the company appears well positioned to capture sustained demand across both established and emerging therapies.
Key Challenges Facing WSTGLP-1 Exposure Continues to Increase Concentration Risk: Although management emphasized diversified growth, GLP-1 therapies remain an increasingly important contributor to West Pharma's financial performance, accounting for approximately 10% of total company revenue. While executives are optimistic about long-term demand, the business remains exposed to changes in reimbursement policies, competitive drug launches, pricing dynamics and regulatory developments affecting obesity and diabetes therapies.
Any slowdown in GLP-1 adoption, unexpected pricing pressure or shift toward alternative treatment modalities could disproportionately affect HVP Component growth. As investors increasingly associate West Pharma's valuation with the GLP-1 market, sustained dependence on this therapeutic category creates an important concentration risk despite improving diversification elsewhere in the portfolio.
Capacity Expansion Remains Constrained by Qualification Timelines: While operational improvements have significantly increased available production capacity, West Pharma's ability to monetize additional demand remains partially constrained by lengthy pharmaceutical qualification processes.
Management indicated that transferring production between manufacturing sites and validating second-source facilities typically require six to 12 months, limiting the speed at which incremental capacity can be utilized. As demand for HVP Components continues to exceed available supply in several product categories, these regulatory and customer qualification requirements may delay revenue realization. Consequently, even with strong end-market demand, the pace of growth remains partly dependent on customer validation timelines that are largely outside the company's direct control.
Estimate TrendWST has been witnessing a stable estimate revision for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has remained unchanged at $8.60 per share, implying a gain of 18% from the prior-year reported level. The consensus mark for revenues is pegged at $3.33 billion, indicating an 8.4% increase from the 2025 reported level.
Other Key PicksSome other top-ranked stocks from the broader medical space are Align Technology (ALGN - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Align Technology reported first-quarter 2026 earnings per share of $2.58, which beat the Zacks Consensus Estimate by 14.2%. Revenues of $1.04 billion surpassed the Zacks Consensus Estimate by 1.8%.
Align Technology has an estimated long-term earnings growth rate of 10.3%. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 7.80%.
Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.3%
Key Takeaways WST completed the sale and transfer of SmartDose 3.5mL manufacturing and supply rights to AbbVie.WST shares have lost 3.1% since July 1 but gained 28.5% year to date against the industry's decline.WST will continue developing other SmartDose platforms, including the 10mL system for larger volumes. West Pharmaceutical Services (WST - Free Report) recently completed the sale and transfer of the manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie (ABBV - Free Report) . The transaction follows the $112.5 million sale agreement with AbbVie announced in January, subject to working capital and other adjustments.
Per management, West Pharmaceutical's pioneering work in on-body delivery technology has improved the lives of people worldwide. Following a portfolio review, the company decided to transfer the SmartDose 3.5mL product to AbbVie to focus on customer development pipeline and advance patient-centered, large-volume on-body delivery solutions that drive durable and profitable growth.
Likely Trend of WST Stock Following the NewsShares of WST have lost 3.1% since the announcement on July 1. Year to date, the stock has gained 28.5% against the industry’s 1.2% decline. The S&P 500 has risen 9.5% in the same timeframe.
The completion of the transaction is likely to support West Pharmaceutical's long-term growth strategy by allowing the company to concentrate resources on higher-growth drug delivery technologies. The divestiture streamlines WST’s product portfolio while reinforcing its commitment to developing innovative solutions for larger-volume injectable medicines.
WST currently has a market capitalization of $25.16 billion.
Image Source: Zacks Investment Research
More on the NewsAt the time of the announcement, the SmartDose 3.5mL platform was expected to contribute approximately 4% of West Pharmaceutical's fiscal 2025 revenues, making it a relatively small part of the company's overall business. The completion of the sale allows West Pharmaceutical to move forward with a more focused portfolio centered on its core drug delivery business.
Following the transaction, the company will continue developing and manufacturing its other SmartDose platforms, including the SmartDose 10mL On-Body Delivery System designed for larger-volume drug delivery.
Industry Prospects Favoring the MarketGoing by data provided by Fortune Business Insights, the on-body drug delivery devices market is anticipated to be valued at $486.43 million in 2026 and is expected to witness a CAGR of 6.9% through 2034.
Factors like the growing demand for on-body drug delivery devices, increasing use of biologic drugs and biosimilars, rising prevalence of chronic diseases, greater adoption of self-administered subcutaneous therapies and a shift toward home-based healthcare are driving the market’s growth.
Other NewsIn June, West Pharmaceutical appointed Michel Lagarde as president, CEO and a member of its board of directors, effective Aug. 31, 2026, succeeding retiring president, CEO and board chair Eric M. Green. As part of the leadership transition, lead independent director Robert F. Friel will assume the role of board chair.
In March, West Pharmaceutical expanded its Dublin facility with a new 165,000 square foot building, significantly boosting its contract manufacturing capacity. The move is aimed at supporting rising global demand for high-volume injectable therapies, particularly in fast-growing areas like diabetes and obesity.
WST’s Zacks Rank & Other Key PicksCurrently, WST carries a Zacks Rank #2 (Buy).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) and Pacific Biosciences of California (PACB - Free Report) .
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 core earnings per share of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Intuitive Surgical has a long-term estimated growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Pacific Biosciences of California, carrying a Zacks Rank #2 at present, reported a first-quarter 2026 adjusted loss per share of 12 cents, which came narrower than the Zacks Consensus Estimate by 29.4%. Revenues of $37.2 million missed the Zacks Consensus Estimate by 9.3%.
Pacific Biosciences of California has an estimated earnings growth rate of 22.6% for 2026. PACB’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 29.8%.
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at West Pharmaceutical Services (WST - Free Report) , which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. West Pharmaceutical Services currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market? In order to see if WST is a promising momentum pick, let's examine some Momentum Style elements to see if this medical device company holds up.
A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.
For WST, shares are up 4.24% over the past week while the Zacks Medical - Dental Supplies industry is up 0.91% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 11.85% compares favorably with the industry's 2.29% performance as well.
Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Shares of West Pharmaceutical Services have increased 37.58% over the past quarter, and have gained 61.48% in the last year. In comparison, the S&P 500 has only moved 14.34% and 21.46%, respectively.
Investors should also take note of WST's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now WST is averaging 763,746 shares for the last 20 days..
Earnings OutlookThe Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with WST.
Over the past two months, 1 earnings estimate moved higher compared to none lower for the full year. This revision helped boost WST's consensus estimate, increasing from $8.50 to $8.60 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been no downward revisions in the same time period.
Bottom LineTaking into account all of these elements, it should come as no surprise that WST is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep West Pharmaceutical Services on your short list.
, /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter 2026 financial results before the market opens on Thursday, July 23, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time.
The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone participants will receive the dial-in number along with a unique PIN number that will enable them to ask questions on the call.
A slide presentation will be made available on the day of the call in the Investors section of the Company's website. A replay of the webcast will be available on the Company's website for approximately 90 days after the event.
About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 26 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.
Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.
Key Takeaways WST climbed nearly 33% YTD after first-quarter revenues jumped 21% and adjusted EPS surged 47%.West Pharma is benefiting from strong GLP-1 demand, with HVP Components posting 23% organic growth.West Pharma raised 2026 guidance as biologics growth and Annex 1 regulations support future expansion. Shares of West Pharmaceutical Services Inc. (WST - Free Report) have staged an impressive comeback in 2026, rising 32.9% year to date. The stock has outpaced the industry’s 30.3% decline and the S&P 500 Index’s 28.2% increase.
The rebound reflects improving investor confidence following a strong first-quarter earnings beat, accelerating demand in high-value injectable drug components and improving growth visibility across biologics and GLP-1 therapies. West Pharma reported first-quarter 2026 revenues of $845 million, up 21% year over year, while adjusted EPS surged 47%.
The strong performance led management to raise full-year guidance. Supported by structural growth in biologics, obesity drugs and injectable therapies, West Pharma appears to be entering a stronger growth cycle, which can extend the current momentum through the remainder of 2026.
WST’s YTD Performance
Image Source: Zacks Investment Research
Factors Supporting the RallyGLP-1 Drug Demand Continues to Drive High-Value Product Growth: Accelerating demand for GLP-1 therapies used to treat obesity and diabetes remains West Pharma's largest growth catalyst.High-Value Product (HVP) components, which account for nearly half of the company's revenues, delivered 23% organic growth in the first quarter.
Management highlighted that GLP-1 products accounted for 10% of total company sales, with demand supported by broader insurance coverage, reduced drug pricing and new indications. Management believes the adoption of oral GLP-1 therapies is expanding the overall market rather than replacing injectable therapies, supporting long-term growth visibility.
Biologics Business Is Emerging as a Durable Long-Term Growth Engine: Beyond GLP-1, biologics continues to be a major structural growth driver. West Pharma reported 26% organic growth in biologics-related business during the first quarter, benefiting from strong commercial wins and growing adoption of its premium NovaPure packaging solutions.
Biosimilar launches globally are expanding therapy usage and increasing demand for injectable packaging solutions. Management emphasized continued strong customer win rates for new biologic launches, suggesting sustained growth beyond the obesity drug cycle.
Annex 1 Regulatory Transition Creates Multi-Year Demand Tailwind: European Annex 1 sterile manufacturing regulations are creating another powerful growth catalyst. West Pharma reported a 66% year-over-year increase in Annex 1-related projects, with management expecting these initiatives to contribute approximately 200 basis points to 2026 revenues.
Pharmaceutical companies are increasingly converting standard components toward higher-value HVP solutions to meet stricter compliance requirements. This transition is also supporting margin expansion, with adjusted operating margin improving 350 basis points to 21.4% in the first quarter.
Strategic Product Portfolio Expansion Strengthens Future Pipeline: Recent strategic moves further improve West Pharma’s long-term positioning. The company completed the divestiture of SmartDose 3.5mL manufacturing rights to AbbVie Inc. (ABBV - Free Report) .
Following this, management will focus on more scalable delivery platforms like SmartDose 10mL. The $112.5 million from AbbVie, following the SmartDose 3.5mL divesture, will boost WST’ cash position, which may lead to higher investment in its high-value product component business. West Pharma expanded its Dublin manufacturing facility to support high-volume injectable therapies, particularly next-generation GLP-1 treatments. The commercial launch of Synchrony S1 prefillable syringe systems also strengthens exposure to the growing biologics and vaccine delivery markets.
WST’s Growth Drivers
Image Source: westpharma.com
Competition Remains Intense as Baxter and BD Push Innovation StrategiesCompetition remains significant from Baxter International Inc. (BAX - Free Report) and Becton Dickinson and Company (BDX - Free Report) , popularly known as BD. Baxter is currently undergoing a turnaround, with Baxter reporting only 3% reported sales growth while facing infusion pump disruptions, manufacturing cost inflation and tariff pressure.
In contrast, BD reported stronger execution, with 2.6% revenue growth and double-digit expansion across biologic drug delivery and advanced monitoring platforms. Compared with Baxter and BD, West Pharma currently demonstrates superior top-line momentum, significantly stronger margin expansion and more direct exposure to high-growth injectable biologics.
While Baxter remains focused on operational recovery and BD continues broad-based innovation expansion, West Pharma’s sharper focus on high-value pharmaceutical packaging gives it a more concentrated growth advantage in 2026. BD and Baxter remain formidable long-term competitors, but West Pharma presently holds stronger growth momentum.
Risks and Challenges Could Moderate Further UpsideDespite strong momentum, risks remain. Rising oil and commodity costs could pressure margins, although management expects mitigation efforts to limit impact. The SmartDose 3.5 divestiture removes a revenue stream that contributed meaningfully in prior periods, creating short-term revenue transition risk.
West Pharma also remains highly dependent on continued injectable GLP-1 demand growth, making it vulnerable if obesity drug adoption slows unexpectedly or oral GLP-1 demand diminishes demand for injections. In addition, increasing competition from Baxter and BD in drug delivery technologies could intensify pricing pressure over time as injectable therapy markets continue expanding globally.
A Glance at WST’s EstimatesThe Zacks Consensus Estimate for WST’s 2026 and 2027 earnings per share (EPS) implies year-over-year growth of 18% and 10.5%, respectively, to $8.60 and $9.50. In the past 60 days, the consensus mark for the company's 2026 EPS has risen 10 cents.
Revenues for 2026 are projected to grow 8.4% to $3.33 billion and another 6.4% to $3.54 billion in 2027.
Image Source: Zacks Investment Research
ConclusionWest Pharma’s strong earnings momentum, structural exposure to GLP-1 therapies, biologics expansion and regulatory-driven product upgrades suggest the stock’s 2026 rally is supported by strong fundamental factors. While competitive and cost pressures remain, the company appears well positioned for continued upside through the rest of 2026.
WST currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
, /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the company completed the sale and transfer of the manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System and associated facilities. The transaction closed as planned on July 1, 2026.
West will continue to develop and manufacture all other versions of SmartDose, including SmartDose® 10mL On-Body Delivery System, adaptive technology for larger volumes.
About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites, including 26 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.
Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 29:
Comfort Systems USA, Inc. (FIX - Free Report) : This engineering services company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.1% over the last 60 days.
Comfort Systems USA’s shares gained 50.6% over the last three months compared with the S&P 500’s decline of 3.7%. The company possesses a Momentum Score of A.
Devon Energy Corporation (DVN - Free Report) : This energy company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 72.7% over the last 60 days.
Devon Energy’s shares gained 23.7% over the last three months compared with the S&P 500’s decline of 3.7%. The company possesses a Momentum Score of A.
West Pharmaceutical Services, Inc. (WST - Free Report) : This pharmaceutical packaging company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.1% over the last 60 days.
West Pharmaceutical Services’ shares gained 26.4% over the past three months compared with the S&P 500’s decline of 3.7%. The company possesses a Momentum Score of A.
You can seethe complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Check out this week’s current list of Best Stocks to Buy Now.
Learn more about theMomentum score and how it is calculated here.
West Pharmaceutical Services (WST - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.
Therefore, the Zacks rating upgrade for West Pharmaceutical basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for West Pharmaceutical imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for West PharmaceuticalThis medical device company is expected to earn $8.50 per share for the fiscal year ending December 2026, which represents no year-over-year change.
Analysts have been steadily raising their estimates for West Pharmaceutical. Over the past three months, the Zacks Consensus Estimate for the company has increased 12.2%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of West Pharmaceutical to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at West Pharmaceutical Services (WST - Free Report) , which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. West Pharmaceutical Services currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market?Let's discuss some of the components of the Momentum Style Score for WST that show why this medical device company shows promise as a solid momentum pick.
Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.
For WST, shares are up 11.85% over the past week while the Zacks Medical - Dental Supplies industry is down 0.85% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 16.55% compares favorably with the industry's 0.78% performance as well.
While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Over the past quarter, shares of West Pharmaceutical Services have risen 26.49%, and are up 36.85% in the last year. In comparison, the S&P 500 has only moved 2.58% and 30.64%, respectively.
Investors should also take note of WST's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now WST is averaging 920,573 shares for the last 20 days..
Earnings OutlookThe Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with WST.
Over the past two months, 6 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost WST's consensus estimate, increasing from $7.94 to $8.50 in the past 60 days. Looking at the next fiscal year, 6 estimates have moved upwards while there have been no downward revisions in the same time period.
Bottom LineGiven these factors, it shouldn't be surprising that WST is a #1 (Strong Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep West Pharmaceutical Services on your short list.
Comerica Bank boosted its holdings in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 31.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 56,693 shares of the medical instruments supplier’s stock after acquiring an additional 13,680 shares during the period. Comerica Bank owned 0.08% of West Pharmaceutical Services worth $15,599,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently modified their holdings of the company. Anchyra Partners LLC acquired a new stake in shares of West Pharmaceutical Services during the 4th quarter worth about $611,000. Concurrent Investment Advisors LLC boosted its stake in shares of West Pharmaceutical Services by 39.3% during the 4th quarter. Concurrent Investment Advisors LLC now owns 1,102 shares of the medical instruments supplier’s stock worth $303,000 after purchasing an additional 311 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in shares of West Pharmaceutical Services by 300.3% during the 4th quarter. Teacher Retirement System of Texas now owns 38,157 shares of the medical instruments supplier’s stock worth $10,499,000 after purchasing an additional 28,626 shares during the last quarter. M&T Bank Corp boosted its stake in shares of West Pharmaceutical Services by 523.7% during the 4th quarter. M&T Bank Corp now owns 128,638 shares of the medical instruments supplier’s stock worth $35,393,000 after purchasing an additional 108,013 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of West Pharmaceutical Services by 13.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,919 shares of the medical instruments supplier’s stock worth $6,581,000 after purchasing an additional 2,922 shares during the period. 93.90% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes A number of research analysts have weighed in on the company. Weiss Ratings raised West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $315.00 price target on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Jefferies Financial Group reissued a “buy” rating and set a $295.00 price target on shares of West Pharmaceutical Services in a research note on Tuesday, February 10th. Morgan Stanley set a $315.00 price target on West Pharmaceutical Services in a research note on Monday. Finally, Zacks Research lowered West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, West Pharmaceutical Services has an average rating of “Moderate Buy” and a consensus price target of $322.89.
View Our Latest Stock Analysis on WST
West Pharmaceutical Services Price Performance WST opened at $292.67 on Wednesday. The company’s 50 day simple moving average is $255.14 and its 200 day simple moving average is $262.77. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. West Pharmaceutical Services, Inc. has a 1 year low of $202.79 and a 1 year high of $322.34. The stock has a market capitalization of $20.68 billion, a PE ratio of 39.13, a P/E/G ratio of 2.65 and a beta of 1.15.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last released its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.45. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The business had revenue of $844.90 million for the quarter, compared to analysts’ expectations of $779.68 million. During the same period last year, the company earned $1.45 earnings per share. The company’s quarterly revenue was up 21.0% on a year-over-year basis. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. As a group, sell-side analysts expect that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current year.
West Pharmaceutical Services Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th will be given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Wednesday, April 29th. West Pharmaceutical Services’s payout ratio is 11.76%.
West Pharmaceutical Services declared that its Board of Directors has authorized a share repurchase plan on Tuesday, February 17th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical instruments supplier to purchase up to 5.6% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.
West Pharmaceutical Services Company Profile (Free Report)
West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.
In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.
Read More Five stocks we like better than West Pharmaceutical Services
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEComerica Bank Sells 2,858 Shares of Synopsys, Inc. $SNPS
NEXT HEADLINE »Comerica Bank Has $15.42 Million Position in Watsco, Inc. $WSO
West Pharmaceutical Services maintains dominant market share in injectable drug delivery, underpinned by a wide moat and robust regulatory positioning. WST reported strong Q1 2026 results, with revenue up 21% and adjusted EPS up 46.9%, prompting a guidance raise and share price rebound. Key growth drivers include biologics market expansion, GLP-1 drug demand, and Annex 1 regulatory upgrades, supporting recurring revenue and margin strength.
From a technical perspective, West Pharmaceutical Services, Inc. (WST - Free Report) is looking like an interesting pick, as it just reached a key level of support. WST's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving average. Typically, a golden cross involves the 50-day and the 200-day moving averages, since bigger time periods tend to form stronger breakouts.
Golden crosses have three key stages that investors look out for. It starts with a downtrend in a stock's price that eventually bottoms out, followed by the stock's shorter moving average crossing over its longer moving average and triggering a trend reversal. The final stage is when a stock continues the upward climb to higher prices.
A golden cross is the opposite of a death cross, another technical event that indicates bearish price movement may be on the horizon.
WST could be on the verge of a breakout after moving 17.5% higher over the last four weeks. Plus, the company is currently a #1 (Strong Buy) on the Zacks Rank.
Looking at WST's earnings expectations, investors will be even more convinced of the bullish uptrend. For the current quarter, there have been 6 changes higher compared to none lower over the past 60 days, and the Zacks Consensus Estimate has moved up as well.
Given this move in earnings estimates and the positive technical factor, investors may want to keep their eye on WST for more gains in the near future.
Shares of West Pharmaceutical Services (WST - Free Report) have been strong performers lately, with the stock up 27% over the past month. The stock hit a new 52-week high of $328.44 in the previous session. West Pharmaceutical has gained 18.5% since the start of the year compared to the -8.2% move for the Zacks Medical sector and the -11% return for the Zacks Medical - Dental Supplies industry.
What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on April 23, 2026, West Pharmaceutical reported EPS of $2.13 versus consensus estimate of $1.68.
For the current fiscal year, West Pharmaceutical is expected to post earnings of $8.5 per share on $3.31 in revenues. This represents a 16.6% change in EPS on a 7.77% change in revenues. For the next fiscal year, the company is expected to earn $9.44 per share on $3.54 in revenues. This represents a year-over-year change of 10.98% and 6.84%, respectively.
Valuation MetricsWest Pharmaceutical may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.
West Pharmaceutical has a Value Score of D. The stock's Growth and Momentum Scores are B and C, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 38.3X current fiscal year EPS estimates, which is a premium to the peer industry average of 14.9X. On a trailing cash flow basis, the stock currently trades at 33.5X versus its peer group's average of 10.2X. Additionally, the stock has a PEG ratio of 2.76. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks RankWe also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, West Pharmaceutical currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if West Pharmaceutical passes the test. Thus, it seems as though West Pharmaceutical shares could have potential in the weeks and months to come.
Investors interested in Medical - Dental Supplies stocks are likely familiar with Align Technology (ALGN - Free Report) and West Pharmaceutical Services (WST - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Align Technology and West Pharmaceutical Services are both sporting a Zacks Rank of #2 (Buy) right now. This means that both companies have witnessed positive earnings estimate revisions, so investors should feel comfortable knowing that both of these stocks have an improving earnings outlook. But this is just one factor that value investors are interested in.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
ALGN currently has a forward P/E ratio of 14.87, while WST has a forward P/E of 38.33. We also note that ALGN has a PEG ratio of 1.44. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. WST currently has a PEG ratio of 2.76.
Another notable valuation metric for ALGN is its P/B ratio of 2.91. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, WST has a P/B of 7.7.
These are just a few of the metrics contributing to ALGN's Value grade of B and WST's Value grade of D.
Both ALGN and WST are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that ALGN is the superior value option right now.
West Pharmaceutical Services Inc. (NYSE:WST) on Monday disclosed a material cybersecurity attack on May 7, saying an unauthorized party exfiltrated data and encrypted certain systems.
After detecting the intrusion on May 4, the company activated incident response protocols, took systems offline globally to contain the breach, notified law enforcement, and hired external cyber-forensic experts.
West Pharmaceutical Restores Core Systems As Investigation ContinuesThe investigation into the scope of the attack and impacted data remains ongoing.
The incident temporarily disrupted global operations, the company noted in an SEC filing.
The pharmaceutical packaging company said it has restored core enterprise systems, while shipping, receiving, and manufacturing activities have resumed at some sites.
Restoration work at remaining sites is still underway, and the company has not provided a timeline for full recovery.
The company said it has not yet determined the financial or operational impact of the incident.
Analyst Sees Near-Term UncertaintyWilliam Blair analyst on Tuesday wrote, "While the disclosure no doubt introduces near-term uncertainty regarding operations and the potential resulting financial implications, we view the company's initial response as swift and comprehensive."
Analyst Matt Larew further added, "However, given the limited visibility into the magnitude and lasting impact of the disruption, we look for further updates from the company, including confirmation of restoration at the remaining impacted sites and additional disclosure quantifying any financial impacts."
William Blair maintains a rating of Outperform for the stock, and that rating is predicated on West being a high-quality, franchise name that provides quality and dependable earnings and cash flow, a clear leadership competitive position, and access to attractive end-market trends without a single product or technology risk.
WST Price Action: West Pharmaceutical shares were down 2.02% at $315.77 at the time of publication on Tuesday, according to Benzinga Pro data. Over the past month, WST has gained about 25.2% versus a 8.2% rise in the S&P 500 and is up roughly 17% year-to-date compared to the index's 6.9% gain.
Hack-Photo TippaPatt via Shutterstock
Market News and Data brought to you by Benzinga APIs
CompaniesMay 15 (Reuters) - West Pharmaceutical Services (WST.N), opens new tab said on Friday its operations were steadily recovering after a cyberattack earlier this month disrupted manufacturing and logistics globally.
The incident first detected on May 4 led the company to take systems offline and restrict access, which temporarily disrupted operations.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Shares of the medical equipment maker were up more than 1% in afternoon trading, after a roughly 7% decline since the incident.
Its high-value product sites, including its largest facility in Eschweiler, Germany, are fully operational, with standard packaging and most West Vantage sites having resumed shipments, the company said.
West did not disclose the financial impact or provide a timeline for full restoration, but said the unauthorized activity had been contained and immediate risks mitigated.
Evercore ISI analyst Daniel Markowitz said he expects some impact to second-quarter results from the cyberattack but does not anticipate any hit to its full-year outlook, adding that the effect is likely already priced into the stock decline.
Markowitz added that flexible capacity could help operations catch up within the quarter, implying potential upside.
Stryker (SYK.N), opens new tab and Intuitive Surgical (ISRG.O), opens new tab also reported cybersecurity incidents in March, while Medtronic (MDT.N), opens new tab disclosed an incident in April.
Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore
Our Standards: The Thomson Reuters Trust Principles., opens new tab
CompaniesMay 20 (Reuters) - West Pharmaceutical Services (WST.N), opens new tab said on Wednesday it has restored operations across its sites after a cybersecurity attack earlier this month and expects the incident to have no material impact on its 2026 financial outlook.
The company said it is continuing its investigation, but has not seen any further unauthorized access.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Shares of the company were up about 2% in after hours trading.
The medical equipment maker detected an intrusion on May 4 and confirmed a material cybersecurity attack on May 7 involving data being taken and systems being locked.
Analysts at Evercore ISI said, "We are incrementally encouraged by WST's ability to quickly return to normal operations and offset any cyberattack-related disruption."
"WST will likely leverage flex capacity and 24/7 operations, which management had previously highlighted as a lever to offset disruption," the analysts added.
The company said after the incident it took systems offline globally, informed law enforcement and brought in external cyber experts to respond to the incident.
It has since restored core systems and restarted key processes such as manufacturing, receiving and shipping at all locations.
The company is now fully operational across manufacturing, supply chain and commercial sites globally, it said.
The company said the review is ongoing, including assessing how much data may have been affected.
The company said the incident has not had and is not expected to have a material impact on its 2026 second-quarter or full-year forecast.
Stryker (SYK.N), opens new tab and Intuitive Surgical (ISRG.O), opens new tab also reported cybersecurity incidents in March, while Medtronic (MDT.N), opens new tab disclosed a similar incident in April.
Reporting by Sahil Pandey in Bengaluru; Editing by Shailesh Kuber
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Key Takeaways West Pharmaceutical's HVP Components grew 23% organically in Q1 2026, led by GLP-1 demand.WST sees Annex 1 upgrades driving premium product adoption and about 200 bps of 2026 growth.West Pharmaceutical faces inflation risks and a $40M second-half 2026 SmartDose revenue headwind. West Pharmaceutical Services, Inc. (WST - Free Report) is well positioned for growth, backed by strong demand for HVPs, expanding GLP-1 drug programs and regulatory-driven Annex 1 conversions. However, tariff impacts, destocking in generics and execution challenges at constrained European facilities are concerning.
Shares of this Zacks Rank #1 (Strong Buy) company have gained 11% year to date compared to the industry's 9.3% decline. The S&P 500 Index has risen 8.1% in the same time frame.
West Pharmaceutical, with a market capitalization of $21.47 billion, is a leading global manufacturer, engaged in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Its earnings are anticipated to improve 13.9% over the next five years. The company delivered a trailing four-quarter average earnings surprise of 19.37%.
Image Source: Zacks Investment Research
Positive Factors Driving WST’s ProspectsHVP Components Growth Reinforcing a Premium Business Mix: West Pharma’s strongest growth driver remains its HVP Components business, which grew 23% organically in the first quarter of 2026, supported by robust demand across GLP-1 and non-GLP-1 applications.
The non-GLP-1 HVP growth accelerated into the high teens, driven by biologics, biosimilars and premiumization through Annex 1 upgrades. The segment’s strength reflects not just cyclical demand, but a structural shift toward premium injectable containment solutions, where West commands higher pricing and margins.
Management also highlighted that over two-thirds of HVP outperformance came from non-GLP-1 products, reducing investor concerns around concentration risk in obesity therapies and reinforcing a more durable long-term growth outlook.
Annex 1 Regulations Creating a Multi-Year Premiumization Tailwind: West Pharma continues to benefit from regulatory tightening around injectable drug sterility, particularly under EU Annex 1 standards, which are driving pharmaceutical customers to upgrade from standard elastomer products to higher-value HVP offerings.
Management expects Annex 1 and HVP conversion to contribute approximately 200 basis points of annual growth in 2026, with momentum accelerating as projects increase 66% year over year. Adoption is beginning to spread beyond Europe into the United States and Asia as manufacturers standardize sterility requirements globally.
Since these upgrades improve average selling prices and margins without requiring major volume increases, Annex 1 represents a high-quality, long-duration growth lever capable of structurally enhancing profitability.
GLP-1 Exposure Remains a Powerful and Expanding Demand Driver: West Pharma’s GLP-1 franchise continues to outperform, with GLP-1-related HVP revenues accounting for 10% of total company sales, supported by strong injectable demand and expanding therapeutic adoption.
Management remains confident that oral GLP-1s are complementing rather than cannibalizing the injectable market, supporting sustained elastomer demand. Additional growth drivers include broader insurance coverage, lower drug pricing, FDA decisions on compounded GLP-1s, new indications beyond diabetes and obesity, and international generic launches. This diversified demand base reduces reliance on a single product cycle and positions West Pharma as a key enabler of one of healthcare’s largest long-term therapeutic opportunities.
Operational Excellence and Capacity Unlock Improving Margins: West Pharma’s operational execution emerged as a significant differentiator in the first quarter, helping adjusted operating margins expand 350 basis points to 21.4%.
Rather than relying solely on new factory buildouts, management is increasing output through process optimization, accelerated onboarding and the transfer of best practices across manufacturing sites.
The company highlighted meaningful productivity gains in Europe that are now being replicated across facilities in the United States, enabling faster scaling of HVP demand with lower incremental capital intensity. This operational leverage not only supports near-term revenue growth but also creates additional upside for margin expansion as fixed manufacturing costs are absorbed more efficiently over time.
Key Challenges Facing WSTCommodity, Fuel and Oil Inflation Could Pressure Margins: West Pharma acknowledged growing cost pressures related to oil, logistics and commodity inflation, particularly following geopolitical disruptions in the Middle East.
While management expects only a single-digit million net impact after mitigation efforts, inflationary pressures remain a meaningful operational risk due to the petroleum-linked nature of elastomer manufacturing and logistics.
Although hedging, pricing actions and operational efficiencies provide partial offsets, sustained energy volatility could compress gross margins if costs rise faster than customer pass-through mechanisms. Given the company’s premium margin profile, even modest inflationary pressure can influence earnings expectations.
SmartDose Divestiture Creates a Second-Half Revenue Headwind: West Pharma continues to expect the midyear divestiture of SmartDose, which creates a notable second-half comparison challenge. Management highlighted an expected $40 million revenue headwind in the back half of 2026 due to the contract roll-off, contributing to a more front-half-weighted revenue profile.
Although the company expects stronger contributions from drug handling and other delivery device businesses over time, there is a timing mismatch between the SmartDose exit and replacement growth. This transition could create temporary volatility in growth rates and operating leverage during the second half of the year.
Estimate TrendWST has been witnessing a positive estimate revision for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has moved north 8.7% to $8.60 per share, implying a gain of 18% from the prior-year reported level. The consensus mark for revenues is pegged at $3.32 billion, indicating an 8% increase from the 2025 reported level.
Other Key PicksSome other top-ranked stocks from the same medical industry are Pacific Biosciences of California (PACB - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .
Pacific Biosciences of California, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 29.4%. Revenues of $37 million missed the Zacks Consensus Estimate by 9.3%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PACB’s earnings are estimated to decline 12.2% in 2027, against the industry’s projected growth of 16.9%. The company has beaten earnings estimates in each of the trailing four quarters, with an average surprise of 29.76%.
Globus Medical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $1.12, which outpaced the Zacks Consensus Estimate by 21.7%. Revenues of $760 million surpassed the Zacks Consensus Estimate by 4%.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% rise. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.26%.
Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which beat the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.
BDSX has an estimated earnings growth rate of 36% for 2026 compared with the industry’s 13.4% rise. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.56%.
On May 21, 2026, West Pharmaceutical Services Inc WST shares rose 3.5% to $316.13. This uptick comes amidst a positive price performance, with shares having traded between a 52-week high of $330.88 and a low of $203.74.
GF Value™ verdict: The current price is $316.13, which is 12.1% below the GF Value™ estimate of $359.79.GF Score™: With a score of 96/100, WST is rated as a strong investment opportunity.Most notable signal: With a Financial Strength rating of 9/10, WST demonstrates robust financial health. Is WST Overvalued or Undervalued? According to the GF Value™, West Pharmaceutical Services Inc WST is currently undervalued, trading at $316.13 compared to an estimated fair value of $359.79. This indicates a margin of safety of approximately 12.1%, suggesting that the shares are priced lower than their intrinsic value. The GF Valuation label classifies WST as "Modestly Undervalued," presenting an opportunity for long-term investors, although caution is warranted due to the stock's recent price performance and market volatility.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Given the current undervaluation, there may be opportunities for price appreciation; however, potential investors should be mindful of market conditions that could impact the stock's future performance.
How Does WST's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 42.3x 43.5x Forward P/E 36.7x N/A West Pharmaceutical Services' current P/E (TTM) of 42.3x is slightly below its 5-year median P/E of 43.5x, indicating that the stock is trading on the lower end of its historical valuation range. The forward P/E of 36.7x further supports this narrative that the stock is reasonably priced relative to its historical valuation. This P/E analysis aligns with the GF Value™ verdict, reinforcing the view that WST is modestly undervalued.
What Does WST's GF Score™ Tell Us? Metric Rating GF Score™ 96 Financial Strength 9/10 Profitability 9/10 Growth 9/10 Valuation 10/10 Momentum 8/10 The GF Score™ of 96/100 reflects the company's overall strong performance across several key areas. West Pharmaceutical Services excels particularly in Valuation with a perfect score of 10/10, indicating that the stock is favorably priced. Financial Strength, Profitability, and Growth all receive high marks of 9/10, underscoring the company's solid financial foundation and robust growth potential. The Momentum Rank of 8/10 suggests a healthy upward price trajectory, though there may be some fluctuations as indicated by recent insider selling activity.
What Are Insiders Doing with WST Stock? In the past three months, insiders at West Pharmaceutical Services Inc have sold approximately $1.1 million worth of shares, with no reported buying activity. This trend of insider selling could suggest a lack of confidence in the stock price's immediate future or possibly a strategic move to capitalize on the stock's recent gains. While insider selling does not necessarily indicate a negative outlook, it is an important signal for investors to consider when evaluating the stock's potential performance.
What This Means for Investors Based on the GF Value™, West Pharmaceutical Services Inc is currently undervalued, presenting a potential opportunity for long-term gains. However, the recent insider selling and market fluctuations warrant a cautious approach as investors assess their strategies moving forward.
For the complete analysis, visit the West Pharmaceutical Services Inc WST stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is WST's GF Score™?
WST's GF Score™ is 96/100, indicating a strong investment opportunity based on various financial metrics.
Is WST overvalued or undervalued?
WST is currently undervalued with a GF Value™ estimate indicating a 12.1% margin of safety.
What is WST's P/E ratio?
WST's P/E (TTM) is 42.3x, which is slightly below its 5-year median of 43.5x, suggesting that the stock is trading at a favorable valuation compared to its historical norms.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovation EXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that its Board of Directors has appointed Michel Lagarde to be President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors starting August 31, 2026.
West Pharmaceutical said on Monday it appointed former Thermo Fisher Scientific executive Michel Lagarde as its top boss, effective August 31, succeeding longtime chief Eric Green.
